pentobarbital will decrease the extent or influence of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. small/importance unidentified.
pentobarbital will lower the level or outcome of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/observe. robust CYP3A4 inducers may perhaps lessen suvorexant efficacy; if greater suvorexant dose necessary, tend not to exceed 20 mg/day
pentobarbital, bupivacaine implant. both will increase toxicity of the other by Other (see comment). Use Caution/watch. Comment: regional anesthetics may well boost the risk of producing methemoglobinemia when concurrently subjected to medicine that read more also bring about methemoglobinemia.
keep track of carefully (one)pentobarbital will minimize the level or result of cannabidiol by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the level or effect of sildenafil by influencing hepatic/intestinal enzyme CYP3A4 metabolism. steer clear of or Use Alternate Drug. powerful CYP3A4 inducers are anticipated to result in substantial decreases in sildenafil plasma amounts
pentobarbital will reduce the extent or influence of fruquintinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. stay away from or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, go on to administer fruquintinib at recommended dosage.
Contraindicated (1)pentobarbital will minimize the level or influence of lonafarnib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib can be a delicate CYP3A4 substrate. Coadministration with strong or reasonable CYP3A4 inducers is contraindicated.
pentobarbital will minimize the extent or outcome of cevimeline by influencing hepatic/intestinal enzyme CYP3A4 metabolism. insignificant/importance unfamiliar.
Contraindicated (one)pentobarbital will decrease the extent or influence of lorlatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the extent or effect of lefamulin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. steer clear of or Use Alternate Drug. Avoid coadministration of lefamulin with potent or average CYP3A inducers unless the reward outweighs challenges. check for lessened efficacy.
pentobarbital will decrease the extent or effect of methylprednisolone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/keep an eye on.
pentobarbital will minimize the extent or outcome of clarithromycin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
pentobarbital will lower the extent or outcome of darifenacin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/keep track of.
using barbiturates as sedatives during the postoperative surgical period of time and as adjuncts to cancer chemotherapy is nicely recognized